期刊
出版社
WILEY
DOI: 10.1002/dad2.12217
关键词
clinical assessment; clinical trials; cognition; computerized assessment; digital cognitive biomarkers; home-based assessment; preclinical Alzheimer's disease; smartphone-based assessment
资金
- National Institutes of Health [R01AG057840, P01AG003991]
- Sahlgrenska Academy
- Anna-Lisa och Bror Bjornssons Foundation
- Handlanden Hjalmar Svensson Foundation
- Carin Mannheimers Prize for Junior Researchers
- Gun & Bertil Stohnes Foundation
- Fredrik och Ingrid Thurings Foundation
- Swedish Neuropsychological Society
- BrightFocus Foundation [A2018202S]
- Knut and AliceWallenberg Foundation [KAW2014.0363]
- Swedish Research Council [2017-02869]
- Swedish government [ALFGBG-813971]
- County Councils ALF-agreement [ALFGBG-813971]
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie [843074]
- Kockska Foundation
- Alzheimerfonden
- National Institute on Aging
- Vinnova [2017-02869] Funding Source: Vinnova
- Swedish Research Council [2017-02869] Funding Source: Swedish Research Council
- Marie Curie Actions (MSCA) [843074] Funding Source: Marie Curie Actions (MSCA)
Digital cognitive assessment shows potential advantages in capturing and tracking cognitive changes in the preclinical stage of Alzheimer's disease. Current research indicates good validity of digital cognitive assessment against Alzheimer's disease biomarkers, and it is expected to play a crucial role in future screening and tracking efforts.
There is a pressing need to capture and track subtle cognitive change at the preclinical stage of Alzheimer's disease (AD) rapidly, cost-effectively, and with high sensitivity. Concurrently, the landscape of digital cognitive assessment is rapidly evolving as technology advances, older adult tech-adoption increases, and external events (i.e., COVID-19) necessitate remote digital assessment. Here, we provide a snapshot review of the current state of digital cognitive assessment for preclinical AD including different device platforms/assessment approaches, levels of validation, and implementation challenges. We focus on articles, grants, and recent conference proceedings specifically querying the relationship between digital cognitive assessments and established biomarkers for preclinical AD (e.g., amyloid beta and tau) in clinically normal (CN) individuals. Several digital assessments were identified across platforms (e.g., digital pens, smartphones). Digital assessments varied by intended setting (e.g., remote vs. in-clinic), level of supervision (e.g., self vs. supervised), and device origin (personal vs. study-provided). At least 11 publications characterize digital cognitive assessment against AD biomarkers among CN. First available data demonstrate promising validity of this approach against both conventional assessment methods (moderate to large effect sizes) and relevant biomarkers (predominantly weak to moderate effect sizes). We discuss levels of validation and issues relating to usability, data quality, data protection, and attrition. While still in its infancy, digital cognitive assessment, especially when administered remotely, will undoubtedly play a major future role in screening for and tracking preclinical AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据